![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GPATCH11 |
Gene summary for GPATCH11 |
![]() |
Gene information | Species | Human | Gene symbol | GPATCH11 | Gene ID | 253635 |
Gene name | G-patch domain containing 11 | |
Gene Alias | CCDC75 | |
Cytomap | 2p22.2 | |
Gene Type | protein-coding | GO ID | GO:0000775 | UniProtAcc | Q8N954 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
253635 | GPATCH11 | HCC1_Meng | Human | Liver | HCC | 3.26e-19 | 3.05e-02 | 0.0246 |
253635 | GPATCH11 | HCC2_Meng | Human | Liver | HCC | 4.27e-04 | 3.28e-02 | 0.0107 |
253635 | GPATCH11 | HCC1 | Human | Liver | HCC | 1.95e-06 | 2.63e+00 | 0.5336 |
253635 | GPATCH11 | HCC2 | Human | Liver | HCC | 4.46e-17 | 3.04e+00 | 0.5341 |
253635 | GPATCH11 | HCC5 | Human | Liver | HCC | 3.91e-05 | 1.04e+00 | 0.4932 |
253635 | GPATCH11 | S014 | Human | Liver | HCC | 8.04e-11 | 3.27e-01 | 0.2254 |
253635 | GPATCH11 | S015 | Human | Liver | HCC | 1.73e-10 | 4.20e-01 | 0.2375 |
253635 | GPATCH11 | S016 | Human | Liver | HCC | 7.60e-21 | 4.64e-01 | 0.2243 |
253635 | GPATCH11 | S027 | Human | Liver | HCC | 3.10e-02 | 2.45e-01 | 0.2446 |
253635 | GPATCH11 | S028 | Human | Liver | HCC | 3.00e-05 | 2.42e-01 | 0.2503 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GPATCH11 | SNV | Missense_Mutation | c.487N>A | p.Ala163Thr | p.A163T | protein_coding | tolerated(0.44) | benign(0.015) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR | ||
GPATCH11 | SNV | Missense_Mutation | c.88G>A | p.Glu30Lys | p.E30K | protein_coding | deleterious(0.01) | possibly_damaging(0.547) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
GPATCH11 | SNV | Missense_Mutation | novel | c.829C>A | p.Pro277Thr | p.P277T | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GPATCH11 | SNV | Missense_Mutation | novel | c.298N>G | p.Phe100Val | p.F100V | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GPATCH11 | SNV | Missense_Mutation | novel | c.47N>T | p.Ala16Val | p.A16V | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
GPATCH11 | SNV | Missense_Mutation | c.237A>C | p.Glu79Asp | p.E79D | protein_coding | tolerated(0.13) | benign(0.021) | TCGA-B5-A11G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
GPATCH11 | SNV | Missense_Mutation | novel | c.271N>G | p.Asn91Asp | p.N91D | protein_coding | tolerated(0.06) | benign(0.281) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
GPATCH11 | SNV | Missense_Mutation | c.654N>T | p.Glu218Asp | p.E218D | protein_coding | tolerated(0.24) | benign(0.014) | TCGA-D1-A2G5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
GPATCH11 | SNV | Missense_Mutation | novel | c.290N>G | p.Asn97Ser | p.N97S | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GPATCH11 | SNV | Missense_Mutation | novel | c.472C>A | p.His158Asn | p.H158N | protein_coding | tolerated(0.42) | benign(0.397) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |